News

Captor Therapeutics nominates the molecular glue CPT-6281 as drug candidate to enter CTA/IND-enabling studies for the treatment of hepatocellular carcinomaa

Captor Therapeutics to attend Wedbush PacGrow Healthcare Conference 2022

Zaproszenie na Walne Zgromadzenie

Captor Therapeutics Q1 2022 report: company continues to generate exciting data on lead projects (CT-01, CT-02, CT-03), maintains strong financial position

Captor Therapeutics to host R&D Day on May 18, 2022

Captor Therapeutics has released its 2021 report. Recent quarterly results have seen significant R&D progress; The Company has sufficient funds for further research and is meeting expenditures on schedule

Captor Therapeutics announces further robust in-vivo efficacy data from CT-01 TPD candidates for hepatocellular carcinoma

Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma

Captor Therapeutics invited to TPD panel at the 8th Annual LSX World Congress 2022

Captor Therapeutics named as the most innovative company on the WSE in the Stock Exchange Company of the Year ranking